Advanced Search

 

Study ID Status Title Patient Level Data
208140/038 Completed Immunogenicity and reactogenicity study of GSK’s DTPa HBV and Hib, either mixed or given in 2 concomitant injections, as a primary vaccination course to healthy infants at the age of 2, 4 and 6 months
208141/001 Completed An open study in healthy Herpes simplex virus (HSV)-positive adults to evaluate the safety of GSK Biologicals’ candidate gD vaccine, with or without 3D MPL
208141/002 Completed Study in healthy HSV positive and HSV negative adults to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' herpes simplex (gD) candidate vaccine with or without 3D-MPL adjuvant administered according to a 0,1, 6 month schedule.
208141/004 Completed A feasibility study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' Herpes simplex candidate vaccine (gD2t), with Monophosphoryl Lipid A (MPL) and with or without Tween in initially HSV-seronegative subjects.
208141/005 Completed A placebo-controlled study to evaluate the efficacy of SmithKline Beecham Biologicals’ herpes simplex candidate vaccine (gD2t) with MPL (Monophosphoryl Lipid A) to prevent genital herpes disease in healthy consorts of subjects with genital herpes disease.
208141/006 Completed A double-blind, randomised study to evaluate the reactogenicity and immunogenicity of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccines (gD2t) with MPL (Monophosphoryl Lipid A), (with or without tween) in healthy HSV-seropositive subjects.
208141/008 Completed An open randomised controlled study to evaluate in initially HSV-seronegative subjects, the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' Herpes simplex candidate vaccine (gD2t-MPL-QS21) with gD2t-Alum-MPL as control.
208141/009 Completed An open, randomised controlled study to evaluate - in HSV-seropositive subjects - the safety, reactogenicity and immunogenicity of SmithKline Beecham Biologicals’ Herpes Simplex candidate vaccine (gD2t-MPL-QS-21), with gD-Al-MPL as control.
208141/014 Completed A double-blind, randomized study to compare, in healthy HSV seronegative subjects, the humoral and cellular immune response of various formulations of herpes simplex candidate vaccines.
208141/015 Completed Study to compare, in healthy HSV seronegative and HSV seropositive subjects, the humoral and cellular immune response of herpes simplex candidate vaccines containing gD from two different cell lines and using gD-Alum as control
208141/016 Completed Study to evaluate the safety of GSK Biologicals’ Herpes Simplex candidate vaccine (gD2t) with MPL in HSV seropositive or seronegative subjects without genital herpes disease
208141/017 Completed Safety of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL & its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease Study Listed on ClinicalStudyDataRequest.com
208141/019 Completed A study comparing the immunogenicity of gD Alum MPL candidate herpes vaccines containing gD produced from 2 different cell lines (CHO DHFR and CHO K1) and at different gD CHO K1 production scales (300L and 600L) in healthy adult HSV seronegative subjects.
208141/023 Completed A double-blind study to compare between groups, in healthy HSV-seronegative adolescent subjects, the humoral and cellular immune response and the reactogenicity of herpes simplex candidate vaccines containing gD (10µg or 20µg) and 2 doses of Al-MPL.
208141/024 Completed A double blind, randomized trial comparing the immunogenicity of 3 commercial scale consistency lots of gD-Alum-MPL vaccine containing CHO K1 gD in healthy HSV seronegative adult subjects.
208141/026 Completed Study comparing different doses and schedules of GSK Bio's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule.
208141/037 Completed Open study to further evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV-1 and HSV-2 seronegative (HSV 1-/2-) women who previously received either alum-MPL or alum as placebo during one of GlaxoSmithKline Biologicals’ phase III studies 208141/005 (HSV-007), 208141/016 (HSV-016) or 208141/017 (HSV-017) Study Listed on ClinicalStudyDataRequest.com
208141/038 Completed Open study to further evaluate the safety, reactogenicity, and immunogenicity of GlaxoSmithKline Biologicals’ prophylactic herpes simplex candidate vaccine with gD-alum-MPL in HSV-1 and HSV-2 seronegative (HSV 1-/2-) women who previously received either alum-MPL or alum as placebo during one of GlaxoSmithKline Biologicals’ Phase III studies 208141/005 (HSV-007), 208141/016 (HSV-016) or 208141/017 (HSV-017) Study Listed on ClinicalStudyDataRequest.com
208141/039 Completed A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who are HSV-1 and -2 Seronegative
208141/040 Completed A study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2‑AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years. Study Listed on ClinicalStudyDataRequest.com
208141/041 Completed Extension to study comparing doses and schedules of GSK's candidate prophylactic herpes simplex virus vaccine (gD-AS04) in healthy HSV- subjects aged 10-15 and 16-18 yrs to healthy HSV- adults (aged 19-45 yrs) receiving the vaccine on a 0-1-6 mth schedule. Study Listed on ClinicalStudyDataRequest.com
208141/042 Completed A Phase III, double-blind, randomized, study to compare: 1) the immunogenicity and safety of 3 commercial scale consistency lots of GlaxoSmithKline (GSK) Biologicals’ herpes simplex candidate vaccine in healthy HSV-1 and -2 seronegative (HSV 1-/2-) female subjects aged 10 – 17 years, and 2) vaccine immunogenicity in healthy HSV 1-/2- females aged 10 – 17 years with healthy HSV 1-/2- adult females Study Listed on ClinicalStudyDataRequest.com
208144/001 Completed A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Mencevax™ ACW135Y vaccine when administered as a single dose to healthy subjects aged 2-30 years.
208144/002 Completed Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged above 2 Years When Administered According to the Prescribing Information.
208355/022 Completed Double-blind randomised comparative assessment of the immunogenicity and reactogenicity of 3 different lots of SB Bios´ combined diphtheria, tetanus, acellular pertussis vaccine.The vaccine will be admin to healthy infants as a primary vaccination course of 3 consecutive doses at 3-4-5 months of age

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.